Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Agreement Will Hasten Development of Alzheimer's Disease Diagnostic Test

By LabMedica International staff writers
Posted on 16 Dec 2009
The availability of an Alzheimer's disease (AD) test targeted to the protein p97 will enable earlier diagnosis, quantitative disease monitoring, and better patient outcomes. More...
The p97 protein is a secreted protein specifically expressed by amyloid plaque-associated reactive microglia.

biOasis Technologies Inc. (South Surrey, BC, Canada) announced that a major step in the application of its p97 test for diagnosis of Alzheimer's disease was achieved by the signing of an agreement with UK-based Fleet Bioprocessing Ltd. (Fleet; Hartley Whitney, UK).

Rob Hutchison, CEO, biOasis commented, ''If earlier diagnosis and improved patient management result in delaying the average onset of the disease by even one-year, society would save in excess of U.S. $12 billion annually. The agreement with Fleet will reduce product development timelines for the biOasis p97 Alzheimer's test and enable faster entry into the $36 billion IVD market."

Fleet Bioprocessing are expert providers of high-quality contract development and manufacturing services. They meet the needs of the diagnostics, pharma, and biotech sectors, offering a range of services from purification and conjugation of proteins, through to immunoassay development and the formulation and dispensing of reagents.

biOasis Technologies Inc. is a company focused on the Health Care & Life Sciences market, and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases.

Related Links:
biOasis Technologies Inc.
Fleet Bioprocessing Ltd.



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.